Suspension of trading

Bellicum Pharmaceuticals, Inc. Share Price

Stocks

BPXA

US0794814048

Biotechnology & Medical Research

OTC Markets Traded
Market Closed - 5-day change 1st Jan Change
- EUR -.--% Intraday chart for Bellicum Pharmaceuticals, Inc. -2.31% -53.99%
3 years 0
Extreme 0
0.19
5 years 0
Extreme 0
0.19
10 years 0
Extreme 0
0.19
Manager TitleAgeSince
Chief Executive Officer 66 23/02/2024
Chief Executive Officer 57 31/01/2017
Director TitleAgeSince
Director/Board Member 57 -
Director/Board Member - -
Date Insider Type Main position Quantity % Market Cap. Importance
22/11/23
Baker Bros. Advisors LP
OptionCompany 42,32,698 44.5721%
03/01/23 Exercice

Director

60,414 0.7014%
03/01/23 Exercice

Director

60,414 0.7014%
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-2.31% - - 8L
-1.79%-3.82%+38.74%+91.90% 6.9TCr
-2.06%-1.52%+46.40%+86.87% 6.63TCr
-0.31%+4.04%-11.99%+457.82% 2.77TCr
+0.86%-6.86%+3.33%-14.78% 2.58TCr
-3.00%-2.61%+34.45%+11.39% 2.65TCr
-1.46%-0.09%+24.64%-18.36% 2.04TCr
-2.96%-16.03%+213.13%+375.00% 1.76TCr
-1.49%-6.69%-4.69%+539.74% 1.51TCr
-0.20%+6.79%+59.66%+159.50% 1.47TCr
Average -1.24%-0.82%+44.85%+187.68% 2.83TCr
Weighted average by Cap. -1.53%-0.45%+40.54%+146.32%

Financials

2021 2022
Net sales 62L 53.39L 50.16L 45.85L 85.79L 59Cr 86.09L 5.93Cr 2.3Cr 30Cr 2.33Cr 2.28Cr 97Cr 15L 12.92L 12.14L 11.09L 20.76L 14Cr 20.83L 1.43Cr 55.71L 7.26Cr 56.32L 55.09L 23Cr
Net income -97.05L -83.58L -78.51L -71.78L -1.34Cr -92Cr -1.35Cr -9.28Cr -3.6Cr -47Cr -3.64Cr -3.56Cr -151.61Cr -2.5Cr -2.15Cr -2.02Cr -1.85Cr -3.46Cr -235.94Cr -3.47Cr -24Cr -9.28Cr -120.94Cr -9.38Cr -9.17Cr -390.13Cr
Net Debt - -
Logo Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals Inc is a United States-based company. The Company operates as a biopharmaceutical company focused on discovering and developing cellular immunotherapies for various forms of cancer.
Employees
13
  1. Stock Market
  2. Stocks
  3. BPXA Stock